Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of LY110140 (fluoxetine) once daily for 52 weeks in Japanese patients with major depressive disorder
jRCT2080222056Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluoxetine in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Primary endpoint: Primary safety outcomes over 52 weeks.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080222056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222056.